Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA) BILLERICA, Mass. , Nov. 17, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement

Conformis Settles Medacta Litigation Related to Patient-Specific Instruments BILLERICA, Mass. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA , Medacta Germany GmbH , and Medacta

BILLERICA, Mass. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) (“Conformis”) announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening of trading on November 10, 2022 , Conformis’ common stock will trade on the

BILLERICA, Mass. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022 .

BILLERICA, Mass. , Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022 , after the market

New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants BILLERICA, Mass. , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc.

BILLERICA, Mass. , Aug. 29, 2022 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate

BILLERICA, Mass. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022 .

Agreement enables interested Vizient members, including academic medical centers, acute care facilities, and ambulatory surgery centers (ASCs), to purchase Conformis knee and hip replacement solutions, including its new Image-to-Implant® Platinum Services℠ Program BILLERICA, Mass. , Aug.

BILLERICA, Mass. , July 28, 2022 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate

BILLERICA, Mass. , July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022 , after the market

As published in The Knee, new study supports Conformis’ longtime assertion that knee joint replacements that are fully personalized to each patient’s unique anatomy may be best to limit post-surgical pain and optimize patient satisfaction BILLERICA, Mass.

BILLERICA, Mass. , May 10, 2022 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate

BILLERICA, Mass. , May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022 .

BILLERICA, Mass. , April 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022 , before the market opens on Wednesday, May 4, 2022 , at approximately 7:00 a.m. Eastern Time .

BILLERICA, Mass. , April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. “We are pleased to announce the addition of Michael Fillion as Chief Operating Officer.

The partnership, announced at the 2022 AAOS conference, will enable patients that have selected a fully personalized Conformis implant – through the company’s Image-to-Implant Platinum Services Program – access to flexible payment options BILLERICA, Mass.

BILLERICA, Mass. , March 14, 2022 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. “We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate

BILLERICA, Mass. , March 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Gary P. Fischetti has been nominated to stand for election to the Company’s Board of Directors at the Company’s 2022 Annual Meeting of Stockholders, scheduled to be held on May 4, 2022 . Mr.

BILLERICA, Mass. , March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2021 .

BILLERICA, Mass. , March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), announced that it was suspending all distribution operations to Russia and any Russian-based entities for its orthopedic medical devices. Additionally, until further notice, the company will no longer pursue

Study included only patients with a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant in their other knee BILLERICA, Mass. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), the pioneer and leader of fully personalized

Independently verified assessment of the performance of the fully personalized iTotal CR system over a 7-year period confirms that it meets the panel’s demanding standards BILLERICA, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that

BILLERICA, Mass. , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate

BILLERICA, Mass. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business Update call on January 6, 2022 , it will release its financial results for the fourth quarter and fiscal year ended December 31, 2021 , after the market closes on

Company Launches Innovative Image-to-Implant ® Platinum Services℠ Program to Better Serve Patients and Surgeons BILLERICA, Mass. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products,

BILLERICA, Mass. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thursday, January 6, 2022 , at approximately 7:00 a.m. Eastern Time .